Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays (Q34656714)

3 August 2017

title

Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays (English)

1 reference

3 August 2017

1 reference

1 reference

J N McAlpine

1 reference

3 August 2017

S M Eisenkop

series ordinal

1 reference

3 August 2017

N M Spirtos

series ordinal

1 reference

3 August 2017

language of work or name

English

0 references

publication date

15 July 2008

1 reference

3 August 2017

1 reference

3 August 2017

volume

110

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

360-364

1 reference

Heterogeneity of human metastatic clones by in vitro chemosensitivity testing. Implications for the clinical application of the clonogenic assay.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

Flow cytometric analysis of lymph node metastases in advanced ovarian cancer: Clinical and biologic significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

Breast cancer survival and in vitro tumor response in the extreme drug resistance assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

Analysis of the clinical utility of a predictive chemosensitivity assay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

Factors associated with success of the extreme drug resistance assay in primary breast cancer specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

Evolution and clinical application of a rapid chemosensitivity assay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

Testing chemotherapeutic combinations in the human tumor colony—forming assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

Chemosensitivity testing of human neoplasms using the soft agar colony assay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

7 January 2021

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

Ovarian cancer: epidemiology, biology, and prognostic factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

Clinical Studies with Modulators of Multidrug Resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

In vitro assay-assisted treatment selection for women with breast or ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

Assay-assisted treatment selection for women with breast or ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.019

10.1016/J.YGYNO.2008.05.019

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference